Beyond the core neuropeptide systems covered in the CBS/PSP Daily Action Plan (Section 93: Neuropeptide Signaling), additional neuropeptides play significant roles in the pathophysiology of 4R-tauopathies. This page provides in-depth coverage of vasopressin, oxytocin, and pituitary adenylate cyclase-activating polypeptide (PACAP) systems, which are implicated in autonomic dysfunction, social cognition deficits, and neuroprotection in corticobasal syndrome and progressive supranuclear palsy.
The neuropeptide systems discussed here represent important therapeutic targets that address non-motor symptoms and may provide disease-modifying effects through neuroprotective mechanisms.
Arginine vasopressin (AVP) is a 9-amino acid neuropeptide synthesized in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus. It plays critical roles in:
AVP signals through three receptor subtypes:
| Receptor | Distribution | Primary Effects |
|---|---|---|
| V1a | Cortex, hippocampus, amygdala | Social behavior, memory, blood pressure |
| V1b (V3) | Pituitary, hypothalamus | ACTH release, stress response |
| V2 | Kidney, hippocampus | Water retention, social memory |
Evidence for vasopressin system involvement in CBS/PSP:
The vasopressin system's role in autonomic regulation makes it particularly relevant for CBS/PSP patients who commonly experience:
V1a receptor antagonists (e.g., conivaptan, tolvaptan):
V1a receptor agonists:
| Agent | Interaction with Levodopa | Interaction with Rasagiline |
|---|---|---|
| Desmopressin | Minimal | Minimal |
| Conivaptan | Monitor BP, additive hypotensive effect | Monitor BP, additive hypotensive effect |
| Tolvaptan | Monitor electrolytes | Monitor electrolytes |
Oxytocin (OT) is a 9-amino acid peptide synthesized in the PVN and SON, distinct from vasopressin but structurally similar. Key functions include:
Oxytocin receptors (OXTR) are widely distributed in:
The oxytocin system is compromised in CBS/PSP:
Social cognitive deficits in CBS/PSP include:
Intranasal oxytocin delivery offers direct CNS access:
| Parameter | Details |
|---|---|
| Dose | 24-40 IU once or twice daily |
| Onset | 30-60 minutes |
| Duration | 2-4 hours |
| Evidence | Moderate in FTD, limited in CBS/PSP |
Potential benefits:
Considerations for CBS/PSP:
| Intervention | Mechanism |
|---|---|
| Social interaction | Endogenous OT release |
| Pet therapy | Animal bonding increases OT |
| Touch/massage | Physical contact stimulates OT |
| Music therapy | Group activities may enhance OT |
| Physical exercise | Moderate exercise elevates OT |
| Agent | Interaction with Levodopa | Interaction with Rasagiline |
|---|---|---|
| Intranasal oxytocin | Monitor for hypotension | Monitor for hypotension |
| Carbetocin | Theoretical interaction | Theoretical interaction |
For CBS/PSP patients with prominent social cognition deficits:
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid neuropeptide discovered in 1989. It belongs to the secretin/glucagon family and exists in two forms:
PACAP receptors:
| Receptor | Distribution | Signaling |
|---|---|---|
| PAC1 | Hypothalamus, cortex, cerebellum | cAMP, IP3, Ca²⁺ |
| VPAC1 | Wide distribution | cAMP |
| VPAC2 | Limbic system, pancreas | cAMP |
PACAP is a potent neuroprotective peptide[2]:
Key neuroprotective mechanisms:
Evidence for PACAP system involvement in CBS/PSP:
The PACAP system's role in:
PACAP-38 (Maxigut):
Synthetic PACAP analogs:
| Strategy | Approach | Evidence |
|---|---|---|
| Peptide delivery | Intranasal PACAP | Preclinical |
| Gene therapy | AAV-PACAP | Phase 1 trials |
| Small molecule | PAC1 agonists | Preclinical |
| Natural compounds | Boost endogenous PACAP | Limited |
| Agent | Interaction with Levodopa | Interaction with Rasagiline |
|---|---|---|
| PACAP-38 | Limited data | Limited data |
| VIP analogs | Minimal | Minimal |
The vasopressin and oxytocin systems have opposing and balancing functions:
| Function | Vasopressin | Oxytocin |
|---|---|---|
| Social behavior | Promotes aggression, rivalry | Promotes affiliation, trust |
| Stress response | Enhances HPA axis | Reduces HPA axis activation |
| Memory | Enhances fear conditioning | Enhances social memory |
| Autonomic | Increases blood pressure | May decrease blood pressure |
In CBS/PSP, both systems are dysregulated, and therapeutic modulation must consider this balance.
The neuropeptide systems discussed here connect to:
For patients with significant neuropeptide system involvement:
Phase 1: Assessment (Weeks 1-2)
Phase 2: Intervention (Weeks 3-8)
| Target | Intervention | Dose | Duration |
|---|---|---|---|
| Oxytocin | Intranasal | 24 IU daily | 4 weeks |
| Social engagement | Non-pharmacological | Daily | Ongoing |
| Autonomic | Compression, hydration | As needed | Ongoing |
| Circadian | Light therapy, melatonin | Evening | Ongoing |
Phase 3: Monitoring (Weeks 9-12)
| Criterion | Score | Rationale |
|---|---|---|
| Mechanism relevance | 8/10 | Oxytocin and vasopressin directly affected by tau pathology; PACAP neuroprotective |
| Therapeutic targeting potential | 6/10 | Limited CNS-penetrant agents; intranasal oxytocin available but evidence limited |
| Evidence level | 4/10 | Strong preclinical for PACAP; moderate clinical for oxytocin; limited for vasopressin |
| Safety profile | 8/10 | Intranasal oxytocin generally safe; vasopressin agents have established safety profiles |
| Accessibility | 5/10 | Intranasal oxytocin off-label; PACAP experimental; vasopressin agents available |
| Combination potential | 7/10 | Combines well with circadian interventions, social engagement strategies |
| Total | 38/60 | Significant pathophysiology; limited but promising therapeutic options |
| Neuropeptide Agent | Levodopa Interaction | Rasagiline Interaction | Management |
|---|---|---|---|
| Intranasal oxytocin | Monitor BP | Monitor BP | Start low, titrate |
| Desmopressin | Minimal | Minimal | Standard monitoring |
| Conivaptan (V1a antagonist) | Additive hypotension | Additive hypotension | Monitor BP closely |
| PACAP-38 | Unknown | Unknown | Monitor, start low |
| Carbetocin | Minimal | Minimal | Standard monitoring |
Key concerns:
Jurek et al. Oxytocin and social cognition in neurodegeneration (2024). 2024. ↩︎
Hadley et al. PACAP signaling in neuroprotection (2023). 2023. ↩︎